Compare BRN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRN | GDTC |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.4M |
| IPO Year | 1995 | 2021 |
| Metric | BRN | GDTC |
|---|---|---|
| Price | $1.13 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 588.7K | 7.3K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,697,000.00 | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.73 |
| 52 Week High | $2.28 | $3.68 |
| Indicator | BRN | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 46.22 |
| Support Level | $1.06 | $0.97 |
| Resistance Level | $1.25 | $1.11 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 64.71 | 35.25 |
Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.